Neuromuscular

As the treatment paradigm for neurologic diseases rapidly progresses, the need for more thorough biomarker tools to measure disease progression and severity has increased, and in recent years, GFAP has emerged as a valuable candidate to add to the existing panel.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 9, 2022.

After showing robust inhibition of biomarkers associated with integrated stress response, the eIF28 modulator will be assessed alongside several other potential agents in the HEALEY ALS Platform trial.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of the American Epilepsy Society.

Neurology News Network for the week ending December 3, 2022. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 2, 2022.

The president and CEO, as well as the executive vice president and chief research officer, of MDA, together offered an in-depth overview of what to expect from the 2023 MDA Conference, which will be held from March 19-22, 2023, in Dallas, Texas. [WATCH TIME: 12 minutes]

The PDUFA date for SRP-9001, developed in partnership between Sarepta and Roche, is set for May 29, 2023. The BLA was submitted for accelerated approval.

The division chief of stroke and vascular neurology at Duke Health provided perspective on the multidisciplinary team needed to treat neuromuscular poststroke symptoms, as well as exciting innovations on the horizon. [WATCH TIME: 4 minutes]

The president of the International Neuropalliative Care Society detailed potential disease states that could benefit from neuropalliative care as well as the importance of the patient community in expanding this type of approach. [WATCH TIME: 4 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is sleep disorders.

Neurology News Network for the week ending November 26, 2022. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 25, 2022.

The codirector of the ALS Center at Washington University School of Medicine detailed the reasons for hope within the ALS space and the promising innovations in the coming future. [WATCH TIME: 4 minutes]

The president of the International Neuropalliative Care Society provided perspective on the growth of the field of neuropalliative care, the organization’s role, and how clinicians are overcoming current barriers in place.

The president of the International Neuropalliative Care Society discussed the area in which neuropalliative has expanded and improved, as well as the potential in the coming years. [WATCH TIME: 2 minutes]

The president of the International Neuropalliative Care Society provided an overview of the organization’s recently concluded conference and the significance of the growth of neuropalliative care. [WATCH TIME: 6 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is neuromuscular disorders.

Neurology News Network for the week ending November 19, 2022. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 18, 2022.

Compared with placebo, a greater proportion of patients on rituximab met the primary end point of minimal disease manifestations at 16 weeks, and demonstrated favorable results on several secondary end points.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with George Small, MD. [LISTEN TIME: 33 minutes]

The division chief of stroke and vascular neurology at Duke Health discussed advantages and capabilities, as well as limitations and barriers of transcranial direct current stimulation to treat poststroke symptoms. [WATCH TIME: 4 minutes]

The codirector of the ALS Center at Washington University School of Medicine in St. Louis provided perspective on the phase 3 VALOR findings of tofersen, an antisense agent currently under review to treat SOD1-mutated ALS.

Zilucoplan, a complement C5 inhibitor, demonstrated a safe and tolerable profile, while meeting its primary and secondary end points in the phase 3 RAISE trial—the basis for its new drug application.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is neuromuscular disorders.